UK markets open in 6 hours 27 minutes
  • NIKKEI 225

    27,689.49
    +107.83 (+0.39%)
     
  • HANG SENG

    25,473.88
    +387.45 (+1.54%)
     
  • CRUDE OIL

    72.33
    -0.06 (-0.08%)
     
  • GOLD FUTURES

    1,807.70
    +8.00 (+0.44%)
     
  • DOW

    34,930.93
    -127.59 (-0.36%)
     
  • BTC-GBP

    28,695.91
    +419.77 (+1.48%)
     
  • CMC Crypto 200

    933.33
    +3.40 (+0.37%)
     
  • ^IXIC

    14,762.58
    +102.01 (+0.70%)
     
  • ^FTAS

    4,024.08
    +13.79 (+0.34%)
     

Nfl Biosciences Raises €5.0m Following Its Successful Initial Public Offering on Euronext Growth Paris®

·4-min read

NFL BIOSCIENCES RAISES €5.0M FOLLOWING ITS SUCCESSFUL INITIAL PUBLIC OFFERING ON EURONEXT GROWTH PARIS®

  • Offer fully subscribed

  • Price set at €3.80 per share

  • Capital increase for a gross total of €5m

  • Settlement-delivery on July 2, 2021 and start of trading on Euronext Growth Paris on July 5, 2021

NFL Biosciences SA, a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing the success of its initial public offering on Euronext Growth Paris® (ISIN: FR0014003XT0, Ticker: ALNFL).

The capital increase was subscribed for by current shareholders, institutional and individual investors, all being sensitive to the global public health impact of innovative and natural prescription drug treatments to treat addictions.

For Ignacio Faus, NFL Biosciences CEO: “We would like to thank all of the shareholders, institutional investors and private individuals who supported us in this capital increase. The proceeds will allow us to further strengthen our organization with various critical recruitments. The company will now focus on the clinical development of NFL-101 for tobacco addiction, while also launching the development of our NFL-201 and NFL-301 programs, in order to treat cannabis addiction and reducing alcohol consumption respectively”.

Bruno Lafont, Chief Operating Officer, adds: “We will now be able to launch our Phase II/III trial with 318 patients for our drug candidate NFL-101, which has already been approved in Australia, a country that is renowned for the quality of its research and where two centers will be opened in Tasmania during the third quarter of 2021. We also plan to open recruitment centers in Europe”.

Results of the Offering

With the public offering in France carried out based on an open price offer (the “Open Price Offer” or the “OPO”) and the global placement with institutional investors (the “Global Placement”) (collectively the “Offering”), a total of 1,315,842 new shares (the “New Shares”) were distributed:

  • 486,205 New Shares for the Open Price Offer. The A1 and A2 orders were allocated in full;

  • 829,637 New Shares for the Global Placement.

During its meeting today, the NFL Biosciences’ Board of Directors therefore acknowledged the partial exercising of the extension clause and set the price for the Open Price Offer at €3.80 per share.

The gross proceeds from the New Shares issued represent approximately €5 million.

Use of the funds raised

The funds raised will enable NFL Biosciences to accelerate its development by:

  • carrying out the Phase II/III trial for its drug candidate NFL-101, for tobacco addiction;

  • recruiting talent to further strengthen its organization;

  • launching the NFL-201 and NFL-301 programs, for the treatment of cannabis addiction and the reduction of alcohol consumption respectively.

Next steps

  • Settlement-delivery: July 2, 2021

  • Admission of the shares on Euronext Growth Paris® and start of trading: July 5, 2021

Share data
Name: NFL Biosciences
Ticker: ALNFL
ISIN: FR0014003XT0
ICB classification: 20103010 – Biotechnology
LEI: 9695006VJWNTN4UNHA27
Eligibility: PEA and PEA-PME

Breakdown of the capital and voting rights

Before transaction

After transaction

Undiluted

Diluted(1)

Undiluted

Diluted(1)

Number of shares

%

Number of shares

%

Number of shares

%

Number of shares

%

Joël Besse

979,690

24.99%

1,229,690

20.35%

1,111,253

21.23%

1,361,253

18.50%

Lafont Family

374,390

9.55%

1,124,390

18.60%

377,679

7.22%

1,127,679

15.32%

Gérard Leduc

76,550

1.95%

1,076,550

17.81%

76,550

1.46%

1,076,550

14.63%

Merau Family

653,050

16.66%

778,050

12.87%

666,206

12.73%

791,206

10.75%

Eric Morel d’Arleux

333,330

8.51%

333,330

5.52%

372,803

7.12%

372,803

5.07%

Nicolas Family

275,320

7.03%

275,320

4.56%

275,320

5.26%

275,320

3.74%

Other private shareholders

1,226,440

31.30%

1,226,440

20.29%

1,242,358

23.73%

1,242,358

16.88%

Float

-

0.00%

-

-

1,112,443

21.25%

1,112,443

15.12%

Total

3,918,770

100.00%

6,043,770

100.00%

5,234,612

100.00%

7,359,612

100.00%

(1) Following the exercising of:

  • 100,000 2018 BSA warrants that may be exercised until July 2, 2023 at a price of €0.50 per share, with one warrant entitling holders to subscribe for 10 shares at a par value of €0.03;

  • 12,500 2019 BSA warrants that may be exercised until March 8, 2026 at a price of €0.30 per share, with one warrant entitling holders to subscribe for 10 shares at a par value of €0.03;

  • 50,000 2018 BSPCE company founder warrants that may be exercised until July 2, 2025 at a price of €0.10 per share, with one warrant entitling holders to subscribe for 10 shares at a par value of €0.03;

  • 50,000 2019 BSPCE company founder warrants that may be exercised until March 8, 2026 at a price of €0.30 per share, with one warrant entitling holders to subscribe for 10 shares at a par value of €0.03.

Holding commitments

For reference, commitments to hold the Company’s shares have been signed by a quota of shareholders representing 100% of the Company’s existing shares and voting rights. These shareholders undertake to retain the shares that they held prior to the capital increase based on:

  • 100% of these shares for six months from the admission of the Company’s shares to trading on the Euronext Growth Paris® market, and

  • 50% for a six-month period starting from the end of the first six-month period.

Transaction partners

Lead manager-investment services provider and
bookrunner

Advisor and
listing sponsor

Legal advisor

Financial
communications

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in Montpellier, France, whose most advanced botanical drug candidate is an aid to stop smoking. Known as NFL-101, this natural nicotine-free product, extracted from standard tobacco leaves, is protected by two patent families. NFL Biosciences aims to offer smokers who would like to stop a safe, natural solution that is effective over the long-term, with short-term personalized administration.

Alongside NFL-101, NFL Biosciences has various development projects focused on botanical drugs for the treatment of cannabis use disorder and alcoholism.

Learn more at www.nflbiosciences.com

Contacts

Bruno Lafont – info@nflbiosciences.com - +33 (0)4 11 93 76 67

Calyptus – nflbio@calyptus.net - +33 (0)1 53 65 68 68

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting